Innate Pharma announces that five abstracts concerning its drug candidates have been selected for the annual meeting of the American Society of Clinical Oncology (ASCO), to be held from May 31 to June 4 in Chicago, USA.

One poster will present final data from the TELLOMAK Phase 2 trial in mycosis fungoides, confirming lacutamab's promising clinical activity, while two others will focus on IPH6501 for the treatment of non-Hodgkin's B lymphoma.

Two other posters, presented by partner AstraZeneca, will focus on phase 2 trials with monalizumab in non-operable stage III non-small cell lung cancer and small cell lung cancer.

Copyright (c) 2024 All rights reserved.